Benign Prostatic Hyperplasia Therapeutics Market Highlights

• Global benign prostatic hyperplasia therapeutics market revenue is poised to garner USD 12.9 billion by 2032 with a CAGR of 5.1% from 2023 to 2032
• North America benign prostatic hyperplasia therapeutics market value occupied around USD 3 billion in 2022
• Asia-Pacific benign prostatic hyperplasia therapeutics market growth will record a CAGR of more than 6% from 2023 to 2032
• Among therapeutic class, the alpha blockers sub-segment generated over US$ 3.9 billion revenue in 2022
• Based on therapy, the combination drug therapy sub-segment generated around 59% share in 2022
• Increasing focus on personalized medicine for BPH treatment is a popular benign prostatic hyperplasia therapeutics market trend that fuels the industry demand

Benign Prostatic Hyperplasia (BPH) Therapeutics refers to the many therapy options for controlling the symptoms and problems of BPH, which is a non-cancerous enlargement of the prostate gland. BPH is most common in elderly men and can result in urinary symptoms such as frequent urination, poor urine flow, incomplete bladder emptying, and urinary tract infections. Several variables influence the need for BPH treatments. To begin, BPH is a common ailment, particularly among older men. As the population ages and life expectancy rises, the number of men having BPH-related symptoms rises, creating a larger demand for appropriate treatment alternatives.

Over the years, there have been tremendous advances in BPH therapies. Alpha-blockers, 5-alpha-reductase inhibitors, and combination therapy have developed as new drugs that provide more focused and effective relief. Furthermore, minimally invasive techniques like as transurethral microwave thermotherapy (TUMT), laser therapy, and prostatic artery embolisation (PAE) have grown in popularity, increasing the desire for novel therapeutic choices.

Finally, growing knowledge of BPH and its impact on quality of life has resulted in an increase in the number of men seeking Combination Drug Therapy assistance for their symptoms. This increased awareness has resulted to an increase in the market for BPH therapies as more people actively seek remedies to manage their disease.

Global Benign Prostatic Hyperplasia Therapeutics Market Dynamics

Market Drivers

• Increasing prevalence of BPH among aging male population
• Growing awareness about BPH and its impact on quality of life
• Advancements in BPH therapeutics, including medications and minimally invasive procedures
• Rising demand for non-surgical treatment options
• Technological innovations improving treatment efficacy and safety

Market Restraints

• Side effects and limitations associated with current BPH medications
• High cost of certain BPH treatment options
• Limited reimbursement coverage in some healthcare systems
• Invasive nature and associated risks of surgical interventions
• Regulatory challenges and approval process for new BPH Therapeutics

Market Opportunities

• Development of novel and targeted BPH medications
• Expansion of minimally invasive procedures and devices
• Emerging markets with a growing geriatric population
• Collaborations and partnerships to drive research and development efforts

Benign Prostatic Hyperplasia Therapeutics Market Report Coverage

Benign Prostatic Hyperplasia (BPH) Therapeutics Market Insights

The rising prevalence of BPH among ageing male populations is a major market driver. As the world's population ages, the number of men having BPH-related symptoms increases, generating a greater need for appropriate treatment alternatives.

Another motivator is increased knowledge of BPH and its influence on quality of life. More people are seeking combination drug therapy treatment for their BPH symptoms as a result of greater knowledge and information transmission, which adds to the need for medicines. This increased knowledge has also resulted in better diagnostic practices and earlier action, propelling the industry even further.

BPH treatment advancements, like as medicines and minimally invasive procedures, are also moving the industry ahead. Alpha-blockers, 5-alpha-reductase inhibitors, and combination therapy have evolved, giving more focused and effective relief for BPH symptoms. Furthermore, as an alternative to surgery, minimally invasive techniques such as transurethral microwave thermotherapy (TUMT), laser therapy, and prostatic artery embolisation (PAE) have gained popularity, increasing the desire for novel therapeutic choices.

However, the BPH therapeutics market is subject to several constraints that may limit its expansion. One of the primary constraints is the adverse effects and limits of existing BPH medicines. Some drugs might induce side effects including dizziness, low blood pressure, and sexual dysfunction, limiting their usage and patient compliance. The high cost of various treatment alternatives, as well as restricted reimbursement coverage in some healthcare systems, is major obstacles to market expansion.

The intrusive nature of surgical procedures for severe instances of BPH, as well as the related dangers, can potentially be a constraint. Many patients may not want surgery as their first treatment option, creating a demand for non-surgical solutions. Furthermore, regulatory constraints and the licensing procedure for novel BPH therapies might be impediments to BPH therapeutics market expansion, necessitating rigorous clinical studies and regulatory compliance.

Despite these obstacles, the BPH treatments industry offers prospects. The discovery of innovative and tailored drugs for the treatment of BPH offers promise. Expanding the availability and accessibility of minimally invasive treatments and equipment can potentially open up new commercial opportunities. Furthermore, rising economies with an ageing population provide unexplored possibilities for BPH therapies. Collaborations and collaborations between pharmaceutical corporations, Combination Drug Therapy device makers, and academic institutes can fuel R&D activities, resulting in novel treatment alternatives and improved patient outcomes.

Benign Prostatic Hyperplasia Therapeutics Market Segmentation

The worldwide market for benign prostatic hyperplasia therapeutics is split based on therapeutics class, therapy, and geography.

Benign Prostatic Hyperplasia Therapeutic Classes

• Alpha blockers
• 5-Alpha Reductase Inhibitors
• Phosphodiesterase-5 Inhibitors
• Others

As per the benign prostatic hyperplasia therapeutics industry analysis, alpha blockers and 5-alpha reductase inhibitors have historically dominated the benign prostatic hyperplasia (BPH) therapeutics market.

Alpha blockers are a class of medications that work by relaxing the muscles in the prostate and bladder neck, thereby improving urine flow and reducing BPH symptoms. They are commonly prescribed to alleviate symptoms such as urinary frequency, urgency, weak stream, and incomplete bladder emptying. Some examples of alpha blockers used in BPH treatment include tamsulosin, alfuzosin, doxazosin, and terazosin.

5-Alpha Reductase Inhibitors (5-ARIs) are another important therapeutic class in the BPH market. These medications work by blocking the conversion of testosterone into dihydrotestosterone (DHT), a hormone that plays a role in prostate growth. By reducing DHT levels, 5-ARIs help shrink the prostate gland, alleviate symptoms, and slow down disease progression. Finasteride and dutasteride are commonly prescribed 5-ARIs for BPH treatment.

Benign Prostatic Hyperplasia Therapeutics Therapies

• Mono Drug Therapy
• Combination Drug Therapy

According to the benign prostatic hyperplasia therapeutics market analysis, mono drug therapy, notably the usage of alpha blockers, was more typically given as a first-line treatment for BPH symptoms. Tamsulosin, alfuzosin, doxazosin, and terazosin are alpha blockers that function by relaxing the smooth muscles in the prostate and bladder neck, increasing urine flow and reducing BPH symptoms. Alpha blockers are extensively used and have shown usefulness in treating BPH symptoms.

However, in recent years, combined medication therapy has gained popularity and is now the main treatment option for more severe instances of BPH. Combination treatment often entails taking an alpha blocker together with a 5-alpha reductase inhibitor (5-ARI), such as finasteride or dutasteride. This method addresses both the dynamic and static components of BPH by relaxing the smooth muscles and shrinking the prostate gland. In terms of symptom alleviation, urine flow improvement, prostate size reduction, and disease progression prevention, combination therapy outperforms mono medication therapy alone.

Benign Prostatic Hyperplasia (BPH) Therapeutics Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

The Middle East & Africa

• South Africa
• GCC Countries
• Rest of the Middle East & Africa (ME&A)

Benign Prostatic Hyperplasia Therapeutics Market Regional Analysis

North America has long been a big market for BPH medicines because to characteristics such as a large ageing population, well-established healthcare infrastructure, and high awareness of BPH. The United States, in particular, is a market leader, because to enhanced treatment choices, research and development initiatives, and favorable reimbursement regulations.

Europe also accounts for a sizable portion of the BPH treatments industry. Countries with powerful healthcare systems and a high prevalence of BPH, such as Germany, France, and the United Kingdom, contribute to the need for treatments. The presence of important market participants, improvements in medical technology, and a focus on personalized medicine characterize the European market.

The BPH treatments market in Asia Pacific is predicted to expand significantly. The region has a huge population, including a sizable elderly population that is vulnerable to BPH. Rising disposable incomes, improved healthcare infrastructure, and more awareness are boosting demand for BPH therapies in nations such as China, Japan, and India. Furthermore, government programmes focused at enhancing urological treatment and boosting access to healthcare are fuelling market expansion.

Benign Prostatic Hyperplasia Therapeutics Market Players

Some of the top benign prostatic hyperplasia therapeutics companies offered in our report include Abbott Laboratories, Astellas Pharma Inc., AbbVie (Allergan Plc), Boehringer Ingelheim Pharma GmbH & Co. KG, GlaxoSmithKline plc., Eli Lilly and Company, Merck & Co., Inc. (Merck Sharp & Dohme Corp), Sanofi, Pfizer Inc., and Teva Pharmaceutical Industries Limited.

Benign Prostatic Hyperplasia Therapeutics Industry Recent Developments

• In December 2021, Eli Lilly published favorable findings from a Phase 3 clinical study of tirzepatide in type 2 diabetic patients. The experiment found that tirzepatide outperformed insulin glargine, a conventional diabetic medication, in terms of blood sugar management and weight reduction. These findings showed that tirzepatide might be a unique therapy option for type 2 diabetic patients.
• Pfizer Inc.: In November 2021, Pfizer disclosed good Phase 3 clinical trial findings for abrocitinib, an oral Janus kinase (JAK) inhibitor being studied for the treatment of moderate to severe atopic dermatitis. The experiment found that abrocitinib improved skin clearance and itch reduction when compared to placebo, emphasising its potential as a targeted treatment for individuals with atopic dermatitis.